Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,212 total articles
Rani Therapeutics announced its Q4 and full-year 2025 financial results along with significant corporate developments. The company secured a collaboration and licensing agreement with Chugai Pharmaceutical valued up to $1.085 billion, successfully completed a $60.3 million private placement, and initiated a Phase 1 clinical trial for RT-114, an ora…
Oxford Industries, owner of brands including Tommy Bahama and Lilly Pulitzer, reported a challenging fiscal 2025 with a 3% decrease in annual net sales to $1.48 billion and a GAAP loss per share of $1.86, impacted by noncash impairment charges and increased tariffs. Despite pressures, the company initiated fiscal 2026 guidance anticipating improved…
CEA Industries provides an update on ongoing efforts to renegotiate its Asset Management Agreement (AMA) with 10X Capital Asset Management LLC. The current Board of Directors seeks to amend the AMA with more favorable terms including reduced management fees, shorter contract term, and adjusted liquidated damages. However, 10X Capital has been uncoo…
TOMI Environmental Solutions, a NASDAQ-listed global company specializing in disinfection and decontamination technologies, announced it will release its fourth quarter 2025 financial results after market close on March 31, 2026, accompanied by a conference call. The company focuses on providing advanced environmental disinfection solutions utilizi…
Iridex Corporation reported Q4 2025 revenues of $14.7 million, up 16% year-over-year, and full-year 2025 revenues of $52.7 million, an 8% increase from 2024. The company achieved positive adjusted EBITDA for the first time recently, driven by growth in glaucoma and retina product sales and reduced operating expenses. Despite global challenges, incl…
Datacentrex, Inc., a digital infrastructure firm specializing in Scrypt-based proof-of-work compute assets, has announced a proposed public offering of its common stock and pre-funded warrants. The net proceeds from this offering are intended to support working capital and general corporate needs. The offering is subject to market conditions and re…
INNOVATE Corp. announced its Q4 and full-year 2025 results featuring a 12.5% revenue increase driven mainly by its Infrastructure segment. The company improved net loss compared to the prior year quarter, boosted backlog to $1.8 billion, and made strides in Life Sciences with FDA approval and a major China system commitment. Despite softness in Spe…
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) announced the submission of its GraftAssureDx transplant rejection test for FDA regulatory review, marking a milestone after 12 years of development. The company reported Q4 2025 revenues of $1.1 million and a full year of $4.1 million, driven by lab services, while gearing up for commercial launch …
VirTra, Inc., a Nasdaq-listed provider of use-of-force and firearms training simulators, reported a 15% revenue decline to $22.4 million for 2025, impacted by an atypical federal funding disruption delaying customer procurement and deliveries. Despite revenue pressures, bookings increased to $26.7 million, and backlog grew to $25.6 million. The com…
Great Southern Bancorp, Inc. announced it will release preliminary earnings for the first quarter of 2026 on April 15 after market close. The company will also hold an investor conference call on April 16 to discuss results. The earnings release and call details will be available on the company’s website and through SEC filings.
Spero Therapeutics announced positive financial results for the fourth quarter and full year of 2025, highlighted by a net income turnaround and increased revenues driven by collaborations with GSK and Pfizer. In December 2025, Spero's licensing partner, GSK, resubmitted the New Drug Application for tebipenem HBr, an oral carbapenem antibiotic for …
LB Pharmaceuticals reported positive results from Phase 2 trials of LB-102 in schizophrenia, initiated pivotal Phase 3 and additional Phase 2 trials for bipolar depression and major depressive disorder, and announced a $100 million private placement. The company has a strong cash position of $295.2 million as of December 31, 2025, providing a runwa…
Rapid7, Inc. announced the acquisition of Kenzo Security, an AI-driven autonomous security platform, to enhance its Command Platform and accelerate preemptive, AI-powered managed detection and response services. The integration aims to improve efficiency in security operations by automating alert investigations and expanding coverage to 100%, reduc…
CTO Realty Growth, a real estate investment trust focusing on open-air shopping centers in the Southeast and Southwest U.S., will report its Q1 2026 financial results on April 28, 2026, followed by a conference call on April 29, 2026. The company also manages Alpine Income Property Trust, Inc. (NYSE: PINE).
Alpine Income Property Trust, Inc., a publicly traded REIT focusing on single tenant net leased commercial properties and commercial loan investments, announced it will release its Q1 2026 financial results after market close on April 23, 2026, followed by a conference call on April 24, 2026. The company aims to provide updates on its portfolio and…
Lifecore Biomedical announced it granted 18,500 restricted stock units (RSUs) as inducement equity to a newly hired employee, under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest after three years, contingent on continued employment. This action is part of Lifecore's efforts to attract talent to its fully integrated CDMO business specializing i…
Arcadia Biosciences announced its financial results for Q4 and full year 2025, reporting a 17% increase in Zola coconut water revenues and significant reductions in SG&A expenses and net cash used in operations. The company also disclosed the termination of a proposed business combination with Roosevelt Resources and the exercise of preferred inves…
SpyGlass Pharma, a late-stage biopharmaceutical company focusing on sustained drug delivery for chronic eye conditions, completed its IPO in February 2026 raising $172.5 million to fund ongoing Phase 3 clinical trials for its BIM-IOL System, intended to treat glaucoma and ocular hypertension patients undergoing cataract surgery. The company reporte…
Xanadu Quantum Technologies Limited has successfully closed its business combination with Crane Harbor Acquisition Corp., a publicly traded SPAC, along with a $275 million PIPE financing. The company will begin trading on Nasdaq and the Toronto Stock Exchange on March 27, 2026, under the ticker symbol XNDU. Xanadu positions itself as the first pure…
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application to Brazil's ANVISA for Palsonify (paltusotine), the first once-daily oral therapy approved in the US for acromegaly. The submission follows positive Phase 3 trial results demonstrating efficacy and tolerability and complements recent regulatory progress in Europe. This ma…
Zentalis Pharmaceuticals reported its full-year 2025 financial results highlighting significant milestones in the development of azenosertib, a potentially first-in-class WEE1 inhibitor targeted at Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Key operational updates include completion of dose confirmation enrollment in the DENALI Pa…
Blink Charging Co. announced its 2025 fourth quarter and full year financial results, highlighting a 45% increase in service revenues, improved operational efficiency with substantial reductions in operating expenses and cash burn, and a successful $20 million equity raise. The company is focusing on expanding its owner-operated DC fast charging ne…
Kyverna Therapeutics reported significant progress in its autoimmune CAR T therapy pipeline, particularly with miv-cel (KYV-101) showing positive clinical results in stiff person syndrome (SPS), generalized myasthenia gravis (gMG), and progressive multiple sclerosis. The company plans a Biologics License Application (BLA) submission for SPS in the …
Precision Optics Corporation, a NASDAQ-listed company specializing in advanced optical instruments for healthcare and defense/aerospace industries, has announced a proposed public offering of common stock. The offering is subject to market conditions, with proceeds intended to support the company's development and manufacturing capacity in next-gen…
Zenas BioPharma has commenced underwritten public offerings of convertible senior notes due 2032 and common stock. The company plans to use net proceeds to support the U.S. commercial launch of obexelimab, advance its clinical development pipeline including Phase 3 trials of orelabrutinib, and for general corporate purposes. The offerings are subje…
